Retrospective multicenter study shows measurable residual disease and KIT mutations predict survival in pediatric acute myeloid leukemia, indicating improved risk stratification.
Background: variants in pediatric CBF-AML. Methods: We retrospectively analyzed 112 children with CBF-AML. We assessed MRD in bone marrow samples collected at diagnosis, the end of induction (EOI), the end of second consolidation (EO2C), and the end of consolidation (EOC) using quantitative reverse transcription PCR with TaqMan assays targeting two fusion transcripts. Results: variant, those who achieved MRD of ≥ 4-LR at EOC had significantly more favorable outcomes. Conclusions: variant status with MRD assessment provides additional prognostic value during treatment.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: